While studies have demonstrated its role in cognitive decline in AD cohorts,34,51 longitudinal analyses are needed to elucidate the temporal dynamics of α-syn SAA positivity and its interplay with co-pathologies like tau and amyloid β, which is crucial for defining α-synuclein’s role in the AD continuum and its impact on anti-amyloid disease-modifying therapies. This evidence concerns the gene MAPT and Alzheimer disease.